Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis.

Lewiecki, E Michael; Miller, Paul D; Harris, Steve T; Bauer, Douglas C; Davison, K Shawn; Dian, Larry; Hanley, David A; McClung, Michael R; Yuen, Chui K; Kendler, David L.
J Clin Densitom; 17(4): 490-5, 2014 Oct-Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24206867